[Therapeutic impact of changing susceptibility of germs causing community-acquired bacterial meningitis in pediatric patients (excluding neonatal period)].
Doit
Catherine
C
Service de Microbiologie, Hôpital Robert-Debré, 48, boulevard Sérurier, 75019 Paris, France.
Bingen
Edouard
E
D000328:Adult; D000367:Age Factors; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D002648:Child; D024881:Drug Resistance, Bacterial; D006801:Humans; D007223:Infant; D008585:Meningitis, Meningococcal / Q000188:drug therapy*; D008586:Meningitis, Pneumococcal / Q000188:drug therapy*; D008826:Microbial Sensitivity Tests; D009345:Neisseria meningitidis / Q000187:drug effects*; D010403:Penicillin Resistance; D017410:Practice Guidelines as Topic; D013296:Streptococcus pneumoniae / Q000187:drug effects*; D013997:Time Factors
D000900:Anti-Bacterial Agents